BullFrog AI Holdings, Inc. announces launch of new scenario-based decision engine for enhanced pharmaceutical R&D strategy. Posted: 1 week, 1 day ago / Feb. 4, 2026 12:41 p.m. UTC BullFrog AI announces a new scenario-based decision engine enhancing AI-driven pharmaceutical R&D strategies, launching March 25. Quiver AI summary. BullFrog AI Holdings, Inc. announced the launch of a new scenario-based decision engine on March 25, 2026, aimed at enhancing its end-to-end AI intelligence workflow for pharmaceutical portfolio strategy and clinical trial design. This innovative technology will provide advanced capabilities beyond traditional tools by employing proprietary algorithms to compare drug programs and trial designs, analyze multiple explicit scenarios, and identify robust strategies that perform well under various conditions. With the aim to improve R&D outcomes in drug development amid a high clinical trial failure rate, the new engine seeks to balance portfolio diversity with risk mitigation. Founder and CEO Vin Singh emphasized that this groundbreaking approach treats strategic scenarios as key inputs, offering insights that no other solution currently provides. For further updates, interested parties can visit the BullFrog AI website. Potential positives. * New scenario-based decision engine enhances BullFrog AI's end-to-end intelligence workflow, setting the company apart from traditional AI decision tools. * The unique capability to evaluate clinical trial strategies and diversified, risk-balanced R&D portfolios could lead to improved outcomes in drug development, addressing the high failure rates in clinical trials. * Introduces a pioneering approach by treating strategic scenarios as first-class inputs, allowing for more informed and flexible R&D strategies unmatched by current market offerings. Potential negatives. * The press release heavily relies on forward-looking statements, which introduces uncertainty regarding the company's future performance and the successful launch of the new capability. * The announcement highlights a significant clinical trial failure rate of 90%, underscoring ongoing challenges in the pharmaceutical industry and the potential limitations of even advanced decision-making tools. * The emphasis on proprietary algorithms and methodologies may raise concerns over transparency and the replicability of results, which could affect investor confidence and market reception. Faq. What is the new technology BullFrog AI is launching? BullFrog AI is launching a scenario-based decision engine to enhance pharmaceutical portfolio strategy and clinical trial design. When will the new capabilities be available? The new capabilities are set to launch on March 25, 2026. How does the new AI capability improve clinical trial strategies? The new AI capability evaluates options using proprietary algorithms, identifying robust program performances across various scenarios. What are the benefits of the scenario-based decision engine? This engine allows for better comparison of drug programs and maintains portfolio diversity while highlighting strong performers for risk mitigation. How does BullFrog AI's approach differ from traditional methods? Unlike traditional methods, BullFrog AI's system treats strategic scenarios as key inputs, avoiding rigid rankings and allowing for more dynamic decision-making. Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here. Receive $BFRG Data Alerts $BFRG hedge fund activity. We have seen 9 institutional investors add shares of $BFRG stock to their portfolio, and 3 decrease their positions in their most recent quarter. Here are some of the largest recent moves: * ANSON FUNDS MANAGEMENT LP added 80,750 shares (+inf%) to their portfolio in Q3 2025, for an estimated $113,050 * J.W. COLE ADVISORS, INC. removed 22,050 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $30,869 * CITADEL ADVISORS LLC added 15,025 shares (+inf%) to their portfolio in Q3 2025, for an estimated $21,035 * XTX TOPCO LTD added 12,916 shares (+inf%) to their portfolio in Q3 2025, for an estimated $18,082 * UBS GROUP AG added 8,075 shares (+113.8%) to their portfolio in Q4 2025, for an estimated $7,128 * MORGAN STANLEY removed 6,476 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $9,066 * VANGUARD GROUP INC added 6,256 shares (+4.1%) to their portfolio in Q4 2025, for an estimated $5,522 To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. Full release. * New capabilities to be launched on March 25 * Unique technology bolsters BullFrog AI's end-to-end AI intelligence workflow with a scenario-based decision engine * Advances current AI decision tools by clearly defining clinical trial strategies and building diversified, risk-balanced R&D portfolios GAITHERSBURG, Md., Feb. 04, 2026 (GLOBE NEWSWIRE) - BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence ("AI") and machine learning to turn complex biomedical data into actionable insights, announces the coming launch of a new scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design. The new AI capability advances the Company's end-to-end intelligence workflow by adding a strategic decision layer on top of existing platforms bfPREP(TM) and bfLEAP(R). Unlike traditional portfolio tools that collapse complex judgments into single scores and fixed weightings, the upcoming offering evaluates options using proprietary algorithms and methodologies revealing which programs are robust winners and which succeed only under narrow conditions. Key capabilities include: * Compares drug programs, indications, and trial designs without forcing arbitrary numerical scores * Tests portfolio decisions against multiple explicit scenarios (e.g., capital-constrained, platform-building, US-first, global) * Identifies options that perform well across strategic futures * Preserves portfolio diversity while surfacing clear leaders to balance concentration with risk mitigation "Each year, more than $200 billion is spent by life science and pharmaceutical companies on research and development, with very low returns given an estimated 90% clinical trial failure rate. While AI adoption in drug discovery has accelerated, strategic portfolio decisions still rely largely on manual scoring and spreadsheet-based tools that force rigid rankings on fundamentally comparative judgments," said BullFrog AI Founder and CEO Vin Singh. "Our new capability takes a different approach by treating strategic scenarios as first-class inputs. It surfaces robust recommendations and highlights options that perform well under multiple strategic futures - enabling clear R&D strategies and the construction of diversified, risk-balanced R&D portfolios. To our knowledge, no other solution in the world can offer this capability." Please visit the BullFrog AI website for updates on the new product launch. About BullFrog AI BullFrog AI leverages artificial intelligence and machine learning to advance drug discovery and development. Through collaborations with leading research institutions, BullFrog AI uses causal AI in combination with its proprietary bfLEAP(R) platform to analyze complex biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials. For more information visit BullFrog AI at: https://bullfrogai.com. Safe Harbor Statement This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "could," "will," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; our and our partners' ability to market and sell our offerings and services, including BullFrog Data Networks(TM); our ability to maintain compliance with Nasdaq listing rules; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

BullFrog AI Holdings, Inc. publishes whitepaper on AI in Bioinformatics and drug development. BullFrog AI announces a whitepaper on leveraging AI for bioinformatics in drug development, addressing data interpretation challenges. Quiver AI summary. BullFrog AI Holdings, Inc. has released a new whitepaper titled "AI in Bioinformatics: Turning Complex Data into Actionable Insights with BullFrog Data Networks(R)." The CEO, Vin Singh, emphasized that the challenge in the life sciences today lies not in data abundance but in its interpretation. The whitepaper identifies major pitfalls in bioinformatics that lead to failures in clinical development and outlines how BullFrog AI's bfLEAP(R) platform utilizes causal inference and probabilistic validation to address these issues. By leveraging its technology in conjunction with BullFrog Data Networks(R), the company aims to create solid foundations for drug development insights. This publication positions BullFrog AI as a leader in utilizing AI for actionable biological understanding, presenting a scalable approach to enhance pharmaceutical research and development processes. Potential positives. * The publication of the whitepaper demonstrates BullFrog AI's leadership in the application of causal AI and bioinformatics, critical areas for value creation in drug development. * BullFrog AI's bfLEAP(R) platform addresses major pitfalls in bioinformatics, potentially reducing failure rates in clinical development and minimizing waste in R&D investments. * The company's modular and scalable approach is positioned to become essential infrastructure for AI-enabled research and development in the pharmaceutical and biotech sectors. Potential negatives. * The press release focuses heavily on the publication of a whitepaper rather than substantial financial or operational updates, which might suggest a lack of significant recent advancements or achievements. * There is an overreliance on forward-looking statements, highlighting potential risks and uncertainties without providing concrete metrics or performance indicators that investors typically seek. What is the main focus of BullFrog AI's new whitepaper? The whitepaper discusses using AI in bioinformatics to transform complex data into actionable insights for drug development. How does BullFrog AI address challenges in bioinformatics? BullFrog AI's bfLEAP(R) platform utilizes causal inference modeling and probabilistic validation to overcome major pitfalls in bioinformatics. What are the key platforms mentioned by BullFrog AI? BullFrog AI highlights its modular approach, combining bfPREP(TM), bfLEAP(R), and BullFrog Data Networks(R) for enhanced pharmaceutical R&D. What issues does the whitepaper identify in modern drug development? The whitepaper identifies issues like the compositional data trap and overreach of generative AI, contributing to high clinical trial failure rates. Where can I access the full whitepaper by BullFrog AI? The full whitepaper is available for download on BullFrog AI's official website. Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here. $BFRG insider trading activity. $BFRG insiders have traded $BFRG stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales. * VININDER SINGH (Chief Executive Officer) sold 29,002 shares for an estimated $43,624 To track insider transactions, check out Quiver Quantitative's insider trading dashboard. $BFRG hedge fund activity. We have seen 8 institutional investors add shares of $BFRG stock to their portfolio, and 8 decrease their positions in their most recent quarter. * ANSON FUNDS MANAGEMENT LP added 80,750 shares (+inf%) to their portfolio in Q3 2025, for an estimated $113,050 * J.W. COLE ADVISORS, INC. removed 22,050 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $30,869 * VIRTU FINANCIAL LLC removed 20,504 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $30,961 * CITADEL ADVISORS LLC added 15,025 shares (+inf%) to their portfolio in Q3 2025, for an estimated $21,035 * XTX TOPCO LTD added 12,916 shares (+inf%) to their portfolio in Q3 2025, for an estimated $18,082 * MORGAN STANLEY removed 6,476 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $9,066 * UBS GROUP AG added 5,803 shares (+449.1%) to their portfolio in Q3 2025, for an estimated $8,124 To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. Full release. GAITHERSBURG, Md., Nov. 18, 2025 (GLOBE NEWSWIRE) - BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence ("AI") and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the publication of a new whitepaper titled "AI in Bioinformatics: Turning Complex Data into Actionable Insights with BullFrog Data Networks(R)." "The life sciences industry has reached an inflection point," said Vin Singh, CEO of BullFrog AI. "Data abundance is no longer the issue - interpretation is. Our technology is designed to cut through the noise, delivering clarity where other AI tools struggle. This whitepaper shows exactly how we're doing that with BullFrog Data Networks(R) and bfLEAP(R), helping pharmaceutical partners move from data overload to data advantage. For investors, it underscores our growing leadership in the application of causal AI and bioinformatics, two of the most critical frontiers for value creation in drug development." Addressing the Bioinformatics Bottleneck The whitepaper identifies three major pitfalls in modern bioinformatics: the compositional data trap, the mirage of feature importance, and the overreach of generative AI. Each contributes to the high failure rate in clinical development and the waste of billions in R&D investments annually. BullFrog AI's bfLEAP(R) platform overcomes these challenges through causal inference modeling and probabilistic validation methods originally developed at the Johns Hopkins Applied Physics Laboratory. When integrated into BullFrog Data Networks(R), these capabilities enable reproducible insights across multimodal datasets - including genomics, transcriptomics, proteomics, and clinical data - creating a foundation for more reliable target identification, biomarker discovery, and patient stratification. The publication reinforces BullFrog AI's expanding role in solving one of the most pressing problems in drug development: the disconnect between massive data availability and actionable biological understanding. The Company believes its modular, scalable approach - combining bfPREP(TM), bfLEAP(R), and BullFrog Data Networks(R)- is well positioned to become a cornerstone of AI-enabled R&D infrastructure for global pharmaceutical and biotech organizations. "Our whitepaper is more than an academic discussion, it's a roadmap for how AI can finally deliver measurable impact in pharma," Mr. Singh added. "We are demonstrating that BullFrog AI's causal and explainable frameworks can make drug development more efficient, predictable, and ultimately, more profitable for our partners and shareholders." The full whitepaper is available for download here. About BullFrog AI BullFrog AI leverages Artificial Intelligence and machine learning to advance drug discovery and development. Through collaborations with leading research institutions, BullFrog AI uses causal AI in combination with its proprietary bfLEAP(R) platform to analyze complex biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials. For more information visit BullFrog AI at: https://bullfrogai.com This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "could," "will," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; our and our partners' ability to market and sell our offerings and services, including BullFrog Data Networks(TM); our ability to maintain compliance with Nasdaq listing rules; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur. Dave Gentry RedChip Companies, Inc. 1-407-644-4256 [email protected]

BullFrog AI to present bfPREP at the AI Drug Discovery & Development Summit 2025. Gaithersburg, MD (GLOBE NEWSWIRE) - BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence ("AI") and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that it will present a technical talk at the upcoming AI Drug Discovery & Development Summit 2025, taking place November 18 - 20, 2025, in Boston, Massachusetts. BullFrog AI's presentation, titled "Human-in-the-Loop Agent Workflows with bfPREP(TM)," will be delivered as part of Technical Insights Session 1 on Wednesday, November 19, 2025. The session will provide an inside look at how BullFrog AI operationalizes AI agents for real-world analytics within its bfPREP(TM) data preparation solution, transforming the "magic" of demos into dependable, reproducible workflows for life sciences organizations. "AI agents can be powerful tools, but reliability in production depends on disciplined engineering and quality control," said Vin Singh, CEO of BullFrog AI. "At this session, we'll share how bfPREP(TM) makes human-in-the-loop AI practical for pharmaceutical data operations, enabling structured outputs, stable schemas, and consistent performance across large, complex datasets. Our technology is not just theoretical; it's being deployed in real-world drug development environments in order to help clients accelerate analytics and make better decisions faster. As we continue to expand the BullFrog Data Networks(TM) platform, we believe bfPREP(TM) could play a defining role in scaling AI adoption across the biopharma industry." bfPREP(TM) is BullFrog AI's dedicated data cleansing and preparation module within its BullFrog Data Networks(TM) Solutions Library. Purpose-built for the life sciences industry, bfPREP(TM) automates the detection, correction, and standardization of clinical, omics, and real-world data, converting fragmented information into analysis-ready datasets. The platform's biomedical-first intelligence and human-in-the-loop validation ensure data integrity and reproducibility, making it a foundational component of BullFrog AI's mission to improve drug development efficiency. Now in its fourth year, the AI Drug Discovery & Development Summit has become a premier global event for innovators applying AI across the pharmaceutical value chain, from early discovery through clinical trials. The 2025 summit will convene 500+ attendees and 100+ expert speakers over three days of technical sessions, keynotes, and networking designed to push the boundaries of AI-driven innovation in drug discovery and development. About BullFrog AI BullFrog AI leverages Artificial Intelligence and machine learning to advance drug discovery and development. Through collaborations with leading research institutions, BullFrog AI uses causal AI in combination with its proprietary bfLEAP(R) platform to analyze complex biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials. For more information visit BullFrog AI at: https://bullfrogai.com Safe Harbor Statement This press release contains forward-looking statements. Drugdiscoveryonline base these forward-looking statements on its expectations and projections about future events, which Drugdiscoveryonline derive from the information currently available to Drugdiscoveryonline. Such forward-looking statements relate to future events or its future performance, including: its financial performance and projections; its revenue and earnings; and its business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "could," "will," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: its ability to change the direction of the Company; its ability to keep pace with new technology and changing market needs; its and its partners' ability to market and sell its offerings and services, including BullFrog Data Networks(TM); its ability to maintain compliance with Nasdaq listing rules; and the competitive environment of its business. These and other factors may cause its actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by Drugdiscoveryonline or its representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about Drugdiscoveryonline. Drugdiscoveryonline is not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by Drugdiscoveryonline or its representatives might not occur.